Roche India’s Antibody Cocktail – Casirivimib and Imdevimad – is now available as a therapy to treat patients with mild and moderate Covid at the Indraprastha Apollo Hospitals in Delhi, the hospital said in a statement on Friday.
The antibody cocktail is administered intravenously and will be administered in a specific area with well-trained healthcare staff taking into account all infection control protocols, it said, adding that cocktail must be ideally administered within 48 to 72 hours of patient testing positive for Covid-19 and before 7 days.
“This treatment has been shown to reduce the risk of hospitalization and fatality rate by 70 per cent and 71 per cent respectively and shortening the duration of symptoms by four days,” it claimed.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…